AMN Healthcare Services, Inc. AMN is well-poised for growth, backed by its wide range of services and strong performance across segments in the first quarter of 2022.Shares of this Zacks Rank #1 (Strong Buy) stock have gained 10.7% against the industry’s decline of 51.5% in a year’s time. The S&P 500 Index has fallen 12% in the same time frame.AMN — with a market capitalization of $4.68 billion — is a travel healthcare staffing company. The company projects 1.1% growth for the next five years and expects to witness continued improvements in its business. AMN Healthcare surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 15.6%.What’s Driving the Performance?AMN Healthcare’s business has gradually evolved beyond traditional healthcare staffing. The company has become a strategic total talent solutions partner with its clients. AMN Healthcare has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. The company enables clients to build and optimize their healthcare talent to deliver great patient outcomes and experience.The company has been displaying strength in digital health capabilities with its AMN Passport and AMN Cares. The first one is the company’s mobile app for healthcare experts, while AMN Cares is a telehealth platform aiding care teams to interface with employees or patients at home.Image Source: Zacks Investment ResearchAll three of AMN Healthcare’s reportable segments witnessed robust performances in the first quarter of 2022. The Nurse and Allied Solutions segment’s revenues soared 87% year over year. Travel nurse staffing revenues grew 95% year over year while Allied division revenues rose 64% year over year. The Physician and Leadership Solutions segment’s revenues were up 27.5% year over year. This upside can be attributed to a 30% growth in locum tenens revenues. Interim leadership revenues were up 14% year over year. Physician and leadership search businesses witnessed revenue growth of 46% year over year.The Technology and Workforce Solutions segment’s revenues climbed 63.8% year over year. Language services business revenues were up 20% year over year, while the vendor management systems (VMS) business improved a whopping 136% year over year.Estimates TrendFor 2022, the Zacks Consensus Estimate for revenues is pegged at $5.02 billion, indicating an improvement of 25.9% from the year-ago period’s reported figure. The same for earnings stands at $10.46, suggesting growth of 30.3% from the prior-year quarter.Other Stocks to ConsiderSome other top-ranked stocks in the broader medical space are Omnicell, Inc. OMCL, Masimo Corporation MASI and ShockWave Medical, Inc. SWAV.Omnicell surpassed earnings estimates in three of the trailing four quarters and missed once, the average surprise being 13.4%. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Omnicell’s long-term earnings growth rate is estimated at 20%. The company’s earnings yield of 3.4% compares favorably with the industry’s (11.7%).Masimo beat earnings estimates in each of the trailing four quarters, the average surprise being 4.4%. The company currently carries a Zacks Rank #2.Masimo’s estimated earnings growth rate for second-quarter 2022 is pegged at 22.3%. The company’s earnings yield is 3.8% against the industry’s (8.5%).ShockWave Medical surpassed earnings estimates in each of the trailing four quarters, the average surprise being 189.9%. The company currently sports a Zacks Rank #1.ShockWave Medical’s earnings growth rate for 2022 is estimated at 807.7%. The company’s earnings yield of 0.9% compares favorably with the industry’s (8%). 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report ShockWave Medical, Inc. (SWAV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research